engleski

Bone Resorption in Hyperthyroid Premenopausal Women on Thyrosuppressant Therapy

Objective: The aim of the study was to investigate the dynamics of bone resorption markers (blood beta-crosslaps, urinary pyridinoline, deoxypyridinoline and hydroxyproline) in hyperthyroid premenopausal women treated with thiamazole. Patient and methods: The study included 45 premenopausal hyperthyroid women with no other cause of increased bone turnover. An informed consent was obtained from all study subjects. Thyroid hormones, TSH and bone resorption markers were determined at baseline, and then at 6 and 18 weeks of treatment. Statistical analysis was perforemd using Wilcoxon matched pair analysis. Results: Thyrosuppressant therapy proved successful. At 6 weeks, elevated T3 and T4 values were measured in only four women, and all women had TSH values below or at the upper reference limit. At 6 weeks, a statistically significant decrease was recorded in blood  -crosslaps, urinary pyridinoline and deoxypyridinoline, and urinary hydroxyproline concentrations (p<0.01 all). At 18 weeks of therapy, all study parameters showed a decrease compared to their 6- week concentrations, however, only the deacrease in the blood beta-crosslap concentration was statistically significant (p<0.05). Conclusion: Although the rate of bone resorption was considerably slowed down by thyrosuppressant therapy, the medians of some markers were still elevated in week 18 (pyridinoline, deoxypyridinole, blood beta-crosslaps), indicating an increased rate of bone resorption in our patients. Sequential determination of any of these markers may be used to determine bone resorption in hyperthyroid patients.

bone resorption markers; hyperthyroid premenopausal women; thyrosuppressant therapy

nije evidentirano